How to deal with the resistance to erlotinib in patients with advanced lung cancer

When patients develop resistance to erlotinib, they should first undergo a comprehensive re-evaluation, including imaging of disease progression and genetic testing. Genetic testing is particularly important because it can help doctors determine whether specific genetic mutations, such as the T790M mutation, are present, which are a common cause of resistance to erlotinib. According to research, about half to two-thirds of patients will develop this mutation after becoming drug-resistant.

Based on the genetic test results, doctors can choose more appropriate treatment options for patients. For example, for patients who are positive for the T790M mutation, third-generation EGFR targeted drugs such as osimertinib may be an effective option. Clinical studies have shown that this type of drug can significantly extend the progression-free survival of patients in post-drug treatment.

If theT790M mutation is not detected, doctors may consider alternative or combination treatment options such as chemotherapy, immunotherapy, or anti-angiogenic drugs. These treatments have shown effectiveness in drug-resistant patients in multiple clinical studies.

Combination therapy is an important trend in the current treatment of lung cancer. Combining erlotinib with other drugs, such as chemotherapy drugs, immunotherapy or new targeted drugs, may help overcome resistance and enhance treatment effectiveness. This strategy has been validated in multiple clinical trials, showing benefit in specific patient populations.

Supportive care is equally important in dealing with drug resistance. This includes managing medication side effects, providing nutritional support and psychological care, among other things. At the same time, paying attention to the patient's quality of life is also an important part of the treatment, ensuring that the patient maintains the best physical and mental state during the treatment process.